Dehydroemetin Chemische Eigenschaften,Einsatz,Produktion Methoden
Pharmazeutische Anwendungen
The synthetic racemic derivative of the plant alkaloid
emetine. Formulated as the hydrochloride for intramuscular
administration.
Like the parent compound, emetine, it
inhibits
E. histolytica at concentrations of 1–10 mg/L in vitro,
but it is more active than the parent in animal models. Drugresistance
in E. histolytica is rare.
No human pharmacokinetic data are available. A halflife
of 2 days, compared with 5 days for emetine, has been
reported. There is selective tissue binding and accumulation
in the liver, lung, spleen and kidney.
It is considerably less toxic than emetine, possibly because
it is more rapidly eliminated. Nevertheless, nausea, vomiting,
diarrhea and abdominal cramps frequently occur.
Neuromuscular effects have also been reported. More serious
cardiotoxic effects can lead to electrocardiogram (EGG)
changes, tachycardia and a drop in blood pressure.
It was formerly used as a second-line treatment in severe
intestinal or hepatic amebiasis, but is no longer recommended
for use.
Dehydroemetin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte